Adrenalin epinephrine vials recalled nationwide due to temperature-abuse deviations
McKesson Medical-Surgical is recalling Adrenalin (epinephrine) 30 mL vials nationwide due to cGMP deviations involving temperature abuse during manufacturing. Temperature excursions may compromise drug potency.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a life-critical emergency medication. While no illnesses or deaths have been reported, temperature abuse of epinephrine could reduce drug potency, creating a risk of harm to patients relying on this medication in emergencies.
Plain-English summary
McKesson Medical-Surgical Inc. is recalling Adrenalin (epinephrine injection, USP) 30 mg/30 mL (1 mg/mL) multiple-dose vials. The recall affects 58 cartons distributed nationwide throughout the United States.
The recall was initiated due to cGMP deviations, specifically temperature abuse during manufacturing. Temperature excursions may affect the potency and safety of the drug.
Customers have been notified with distribution dates and shipment dates to help identify potentially affected product. McKesson Medical-Surgical was unable to identify specific lot numbers but has provided customers with timeframes to determine if their product may have been affected.
The recalled product
- Product
- ADRENALIN (EPINEPHRINE)
- Brand
- ADRENALIN
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Hazard
- temperature-abuse
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
UPCs (1)
- 0342023168016
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ADRENALIN
- HighAdrenalin Epinephrine Injection Recalled Due to Incorrect Expiration Date Label
FDA (Drugs) · 2024-02-28
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27